[{"id":"2dee9945-f549-4f20-8162-2f885a4bbaeb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05887492","created_at":"2023-06-02T14:06:23.752Z","updated_at":"2025-02-25T13:49:51.075Z","phase":"Phase 1/2","brief_title":"Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","source_id_and_acronym":"NCT05887492","lead_sponsor":"Tango Therapeutics, Inc.","biomarkers":" STK11","pipe":" | ","alterations":" STK11 mutation","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • TNG260"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 06/12/2023","start_date":" 06/12/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-21"},{"id":"757c7ea9-28ea-4973-bbc9-a09748839d13","acronym":"","url":"https://clinicaltrials.gov/study/NCT05039801","created_at":"2021-09-10T16:57:15.373Z","updated_at":"2025-02-25T15:35:16.395Z","phase":"Phase 1","brief_title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05039801","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2","pipe":" | ","alterations":" PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation","tags":["PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • Truqap (capivasertib) • IPN60090"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/09/2021","start_date":" 09/09/2021","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 05/29/2026","study_completion_date":" 05/29/2026","last_update_posted":"2025-02-10"},{"id":"d8999917-3c0d-4b22-aa4a-6a2e1a2de773","acronym":"TRITON","url":"https://clinicaltrials.gov/study/NCT06008093","created_at":"2023-08-23T15:11:10.888Z","updated_at":"2025-02-25T16:55:15.589Z","phase":"Phase 3","brief_title":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients","source_id_and_acronym":"NCT06008093 - TRITON","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • KRAS • ALK • STK11 • KEAP1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • STK11 mutation • ALK fusion • KEAP1 mutation","tags":["EGFR • KRAS • ALK • STK11 • KEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • STK11 mutation • ALK fusion • KEAP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 04/04/2024","start_date":" 04/04/2024","primary_txt":" Primary completion: 08/17/2027","primary_completion_date":" 08/17/2027","study_txt":" Completion: 03/20/2031","study_completion_date":" 03/20/2031","last_update_posted":"2025-02-04"},{"id":"24c0fcb4-b357-4530-a6a0-668b57518e71","acronym":"ARC-27","url":"https://clinicaltrials.gov/study/NCT06120075","created_at":"2023-11-07T16:14:23.781Z","updated_at":"2025-02-25T17:32:32.864Z","phase":"Phase 1","brief_title":"A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies","source_id_and_acronym":"NCT06120075 - ARC-27","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" EGFR • PD-L1 • ALK • MET • RET • ROS1 • STK11 • NTRK","pipe":" | ","alterations":" EGFR mutation • STK11 mutation • ALK mutation","tags":["EGFR • PD-L1 • ALK • MET • RET • ROS1 • STK11 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • STK11 mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Yutuo (zimberelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 01/19/2024","start_date":" 01/19/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-01-30"},{"id":"aba33b5e-2046-4e2a-9fb8-ed489862ca5d","acronym":"NAUTIC","url":"https://clinicaltrials.gov/study/NCT06494540","created_at":"2025-02-25T17:53:16.413Z","updated_at":"2025-02-25T17:53:16.413Z","phase":"","brief_title":"NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations","source_id_and_acronym":"NCT06494540 - NAUTIC","lead_sponsor":"AstraZeneca","biomarkers":" KRAS • STK11","pipe":" | ","alterations":" KRAS mutation • STK11 mutation","tags":["KRAS • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 06/28/2024","start_date":" 06/28/2024","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-01-29"},{"id":"0722b240-7848-480e-91ab-a7a7c502ac66","acronym":"","url":"https://clinicaltrials.gov/study/NCT05445843","created_at":"2022-07-06T14:54:25.537Z","updated_at":"2024-07-02T16:34:27.361Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression \u003c 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.","source_id_and_acronym":"NCT05445843","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PD-L1 • KRAS • STK11","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12 • KRAS G12C + PD-L1 expression","tags":["PD-L1 • KRAS • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12 • KRAS G12C + PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e opnurasib (JDQ443)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 12/06/2022","start_date":" 12/06/2022","primary_txt":" Primary completion: 11/02/2026","primary_completion_date":" 11/02/2026","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-06-11"},{"id":"b28a300d-a648-41cb-b9b3-e37a6c33dd25","acronym":"LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT04173507","created_at":"2021-01-18T20:21:36.422Z","updated_at":"2024-07-02T16:34:59.352Z","phase":"Phase 2","brief_title":"Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)","source_id_and_acronym":"NCT04173507 - LUNG-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" STK11","pipe":" | ","alterations":" STK11 mutation","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Talzenna (talazoparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 02/14/2020","start_date":" 02/14/2020","primary_txt":" Primary completion: 11/24/2021","primary_completion_date":" 11/24/2021","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-04"},{"id":"7315975a-48e7-478f-a922-63b5c722e7c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03872427","created_at":"2021-01-18T19:05:39.832Z","updated_at":"2024-07-02T16:35:03.365Z","phase":"Phase 2","brief_title":"Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study","source_id_and_acronym":"NCT03872427","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" STK11 • NF1 • KEAP1 • NFE2L2","pipe":" | ","alterations":" STK11 mutation • NF1 mutation • KEAP1 mutation • NFE2L2 mutation","tags":["STK11 • NF1 • KEAP1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation • NF1 mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e telaglenastat (CB-839)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 12/14/2019","start_date":" 12/14/2019","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2024-05-16"},{"id":"1fffbecc-9d1d-4405-aa75-3725ff51616b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05807048","created_at":"2023-04-10T14:03:23.661Z","updated_at":"2024-07-02T16:35:07.816Z","phase":"Phase 2","brief_title":"Daratumumab in STK11 Mutated NSCLC","source_id_and_acronym":"NCT05807048","lead_sponsor":"NYU Langone Health","biomarkers":" STK11","pipe":" | ","alterations":" STK11 mutation","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex Faspro (daratumumab and hyaluronidase-fihj)"],"overall_status":"Recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-24"},{"id":"46d378ac-a32a-49b5-8f63-3c539b277a13","acronym":"QPCS","url":"https://clinicaltrials.gov/study/NCT04104230","created_at":"2021-01-18T20:04:23.369Z","updated_at":"2024-07-02T16:35:09.050Z","phase":"","brief_title":"Quebec Pancreas Cancer Study","source_id_and_acronym":"NCT04104230 - QPCS","lead_sponsor":"George Zogopoulos","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":" | ","alterations":" ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 03/12/2012","start_date":" 03/12/2012","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-04-17"},{"id":"5d2f8237-eb79-4c19-a52b-8af11ae90986","acronym":"","url":"https://clinicaltrials.gov/study/NCT02775461","created_at":"2021-01-18T13:36:36.959Z","updated_at":"2024-07-02T16:35:21.683Z","phase":"","brief_title":"Pancreas Registry and High Risk Registry","source_id_and_acronym":"NCT02775461","lead_sponsor":"Icahn School of Medicine at Mount Sinai","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MSH2","pipe":" | ","alterations":" ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1116","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 11/01/2033","primary_completion_date":" 11/01/2033","study_txt":" Completion: 11/01/2033","study_completion_date":" 11/01/2033","last_update_posted":"2024-01-30"},{"id":"6bfc50c2-c588-42c4-845a-93a67a444c47","acronym":"CodeBreaK 201","url":"https://clinicaltrials.gov/study/NCT04933695","created_at":"2021-06-22T15:52:33.008Z","updated_at":"2024-07-02T16:35:33.945Z","phase":"Phase 2","brief_title":"A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment","source_id_and_acronym":"NCT04933695 - CodeBreaK 201","lead_sponsor":"Amgen","biomarkers":" PD-L1 • KRAS • STK11","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12","tags":["PD-L1 • KRAS • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 01/28/2022","start_date":" 01/28/2022","primary_txt":" Primary completion: 11/14/2024","primary_completion_date":" 11/14/2024","study_txt":" Completion: 11/14/2024","study_completion_date":" 11/14/2024","last_update_posted":"2023-10-11"},{"id":"a2c0ab58-6cde-42b8-9e69-6e1ed22c988f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05469178","created_at":"2022-07-21T11:55:16.592Z","updated_at":"2024-07-02T16:35:34.196Z","phase":"Phase 1b/2a","brief_title":"A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05469178","lead_sponsor":"BerGenBio ASA","biomarkers":" PD-L1 • STK11","pipe":" | ","alterations":" STK11 mutation","tags":["PD-L1 • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • pemetrexed • bemcentinib (BGB324)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 12/14/2022","start_date":" 12/14/2022","primary_txt":" Primary completion: 08/11/2025","primary_completion_date":" 08/11/2025","study_txt":" Completion: 08/11/2025","study_completion_date":" 08/11/2025","last_update_posted":"2023-10-09"},{"id":"02e9230b-7c6e-47e9-b7b8-543fbe0eb06e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457101","created_at":"2022-07-13T11:56:51.208Z","updated_at":"2024-07-02T16:35:45.200Z","phase":"","brief_title":"Validation of an AI-based Biliopancreatic EUS Navigation System for Real-time Quality Improvement: A Prospective, Single-center, Randomized Controlled Trial","source_id_and_acronym":"NCT05457101","lead_sponsor":"Renmin Hospital of Wuhan University","biomarkers":" BRCA1 • BRCA2 • STK11 • MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" BRCA1 mutation • STK11 mutation • PALB2 mutation • MSH2 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • STK11 • MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • STK11 mutation • PALB2 mutation • MSH2 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 264","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 07/30/2023","study_completion_date":" 07/30/2023","last_update_posted":"2023-06-22"},{"id":"2aa710a5-3fe6-42b3-a2fa-b67d5b9d5717","acronym":"","url":"https://clinicaltrials.gov/study/NCT03991819","created_at":"2021-01-18T19:37:30.657Z","updated_at":"2024-07-02T16:35:45.501Z","phase":"Phase 1","brief_title":"Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03991819","lead_sponsor":"University Health Network, Toronto","biomarkers":" EGFR • PD-L1 • KRAS • BRAF • ALK • STK11","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • ALK rearrangement • EGFR wild-type • STK11 mutation","tags":["EGFR • PD-L1 • KRAS • BRAF • ALK • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • ALK rearrangement • EGFR wild-type • STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Mektovi (binimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/20/2019","start_date":" 09/20/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-06-16"},{"id":"cb6e094e-2742-489c-80fc-e3915d2584c6","acronym":"PREPAIRD","url":"https://clinicaltrials.gov/study/NCT05740111","created_at":"2023-02-22T15:01:18.890Z","updated_at":"2024-07-02T16:35:54.968Z","phase":"","brief_title":"The PREPAIRD Study: Personalized Surveillance for Early Detection of Pancreatic Cancer in High Risk Individuals","source_id_and_acronym":"NCT05740111 - PREPAIRD","lead_sponsor":"Oslo University Hospital","biomarkers":" TP53 • STK11 • CDKN2A • PRSS1","pipe":" | ","alterations":" TP53 mutation • STK11 mutation • CDKN2A mutation","tags":["TP53 • STK11 • CDKN2A • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • STK11 mutation • CDKN2A mutation"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 200","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 12/31/2042","primary_completion_date":" 12/31/2042","study_txt":" Completion: 12/31/2042","study_completion_date":" 12/31/2042","last_update_posted":"2023-02-22"},{"id":"49802c3e-ce1e-4e25-99ea-df4984c5d29c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05276726","created_at":"2022-03-11T14:53:34.119Z","updated_at":"2024-07-02T16:36:03.348Z","phase":"Phase 1/2","brief_title":"A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1","source_id_and_acronym":"NCT05276726","lead_sponsor":"Jacobio Pharmaceuticals Co., Ltd.","biomarkers":" KRAS • STK11 • KEAP1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • STK11 mutation • KEAP1 mutation • KRAS G12","tags":["KRAS • STK11 • KEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • STK11 mutation • KEAP1 mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Airuikai (glecirasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 08/17/2022","start_date":" 08/17/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2022-09-28"},{"id":"053f27e7-25b9-4207-ab75-19a39c4c5d38","acronym":"","url":"https://clinicaltrials.gov/study/NCT03693378","created_at":"2021-01-18T18:06:04.652Z","updated_at":"2024-07-02T16:36:14.357Z","phase":"","brief_title":"A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups","source_id_and_acronym":"NCT03693378","lead_sponsor":"Immunovia, Inc.","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":" | ","alterations":" ATM mutation • STK11 mutation • PALB2 mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • STK11 mutation • PALB2 mutation"],"overall_status":"Completed","enrollment":" Enrollment 1349","initiation":"Initiation: 01/19/2016","start_date":" 01/19/2016","primary_txt":" Primary completion: 11/12/2021","primary_completion_date":" 11/12/2021","study_txt":" Completion: 11/12/2021","study_completion_date":" 11/12/2021","last_update_posted":"2022-03-31"},{"id":"71f1c969-b84a-461e-abff-6a5fd7a94ebc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02535650","created_at":"2021-01-17T17:10:25.985Z","updated_at":"2024-07-02T16:36:15.904Z","phase":"Phase 2","brief_title":"Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma","source_id_and_acronym":"NCT02535650","lead_sponsor":"Samsung Medical Center","biomarkers":" STK11 • HRAS","pipe":" | ","alterations":" STK11 mutation • HRAS mutation","tags":["STK11 • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 11/12/2015","start_date":" 11/12/2015","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2022-03-08"},{"id":"1ae6c471-6445-4fd2-b871-72286488e80f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03304990","created_at":"2021-01-18T16:19:29.757Z","updated_at":"2024-07-02T16:36:42.943Z","phase":"","brief_title":"Panomics Relationships in the Epidemiology of Cancer Through In Silico Expression (PRECISE)","source_id_and_acronym":"NCT03304990","lead_sponsor":"Greater Baltimore Medical Center","biomarkers":" TP53 • BRCA1 • BRCA2 • PTEN • STK11 • VHL","pipe":" | ","alterations":" TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation • STK11 mutation • VHL mutation","tags":["TP53 • BRCA1 • BRCA2 • PTEN • STK11 • VHL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation • STK11 mutation • VHL mutation"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/29/2018","start_date":" 11/29/2018","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2020-07-22"},{"id":"a6d7668a-de1a-4dc8-8fcb-764c0dc2a8d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02613923","created_at":"2021-01-18T12:41:56.434Z","updated_at":"2024-07-02T16:36:59.796Z","phase":"","brief_title":"A Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer","source_id_and_acronym":"NCT02613923","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" TP53 • BRCA1 • BRCA2 • PTEN • STK11 • CDH1","pipe":" | ","alterations":" TP53 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation • STK11 mutation","tags":["TP53 • BRCA1 • BRCA2 • PTEN • STK11 • CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA1 mutation • PTEN deletion • PTEN mutation • STK11 mutation"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 08/04/2015","start_date":" 08/04/2015","primary_txt":" Primary completion: 03/23/2017","primary_completion_date":" 03/23/2017","study_txt":" Completion: 07/23/2017","study_completion_date":" 07/23/2017","last_update_posted":"2019-05-09"},{"id":"f9282959-da1a-4277-9eb2-00db5cf8baa3","acronym":"CAPS4","url":"https://clinicaltrials.gov/study/NCT00714701","created_at":"2021-01-18T02:40:29.986Z","updated_at":"2024-07-02T16:37:07.112Z","phase":"","brief_title":"Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study)","source_id_and_acronym":"NCT00714701 - CAPS4","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" BRCA1 • BRCA2 • STK11 • CDKN2A","pipe":" | ","alterations":" STK11 mutation • PALB2 mutation • CDKN2A mutation","tags":["BRCA1 • BRCA2 • STK11 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation • PALB2 mutation • CDKN2A mutation"],"overall_status":"Completed","enrollment":" Enrollment 631","initiation":"Initiation: 06/01/2008","start_date":" 06/01/2008","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 07/01/2016","study_completion_date":" 07/01/2016","last_update_posted":"2018-09-07"}]